Detailed Information on Publication Record
2018
Deleterious Effect of Advanced CKD on Glyoxalase System Activity not Limited to Diabetes Aetiology
PÁCAL, Lukáš, Katarína CHALÁSOVÁ, Anna PLESKAČOVÁ, Jitka REHOROVA, Josef TOMANDL et. al.Basic information
Original name
Deleterious Effect of Advanced CKD on Glyoxalase System Activity not Limited to Diabetes Aetiology
Authors
PÁCAL, Lukáš (203 Czech Republic, guarantor, belonging to the institution), Katarína CHALÁSOVÁ (703 Slovakia, belonging to the institution), Anna PLESKAČOVÁ (203 Czech Republic, belonging to the institution), Jitka REHOROVA (203 Czech Republic), Josef TOMANDL (203 Czech Republic) and Kateřina KAŇKOVÁ (203 Czech Republic, belonging to the institution)
Edition
International Journal of Molecular Sciences, Basel, Switzerland, MDPI AG, 2018, 1422-0067
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10608 Biochemistry and molecular biology
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 4.183
RIV identification code
RIV/00216224:14110/18:00101254
Organization unit
Faculty of Medicine
UT WoS
000435297000253
Keywords in English
glyoxalase; diabetes; chronic kidney disease; diabetic nephropathy
Tags
International impact, Reviewed
Změněno: 9/2/2019 22:00, Soňa Böhmová
Abstract
V originále
Methylglyoxal production is increased in diabetes. Methylglyoxal is efficiently detoxified by enzyme glyoxalase 1 (GLO1). The aim was to study the effect of diabetic and CKD milieu on (a) GLO1 gene expression in peripheral blood mononuclear cells; (b) GLO1 protein levels in whole blood; and (c) GLO1 activity in RBCs in vivo in diabetic vs. non-diabetic subjects with normal or slightly reduced vs. considerably reduced renal function (CKD1-2 vs. CKD3-4). A total of 83 subjects were included in the study. Gene expression was measured using real-time PCR, and protein levels were quantified using Western blotting. Erythrocyte GLO1 activity was measured spectrophotometrically. GLO1 gene expression was significantly higher in subjects with CKD1-2 compared to CKD3-4. GLO1 protein level was lower in diabetics than in non-diabetics. GLO1 activity in RBCs differed between the four groups being significantly higher in diabetics with CKD1-2 vs. healthy subjects and vs. nondiabeticsfig with CKD3-4. GLO1 activity was significantly higher in diabetics compared to nondiabetics. In conclusion, both diabetes and CKD affects the glyoxalase system. It appears that CKD in advanced stages has prevailing and suppressive effects compared to hyperglycaemia. CKD decreases GLO1 gene expression and protein levels (together with diabetes) without concomitant changes of GLO1 activity.
Links
| GA16-14829S, research and development project |
|